Multiplikator Forward P/S Ascentage Pharma Group (AAPG)

Logo perusahaan publik Ascentage Pharma Group International (AAPG)

The forward P/S multiple for Ascentage Pharma Group (AAPG) reflects the impact of geopolitical tensions between Beijing and Washington on share prices, with the current value standing at 8.50. Environmental responsibility regarding chemical disposal is coupled with serious challenges: prolonged waiting periods for regulatory verdicts and significant costs associated with the final stages of clinical drug trials.

Ascentage Pharma - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AAPG (periode 25.01.2025 - 13.11.2026)

Rincian analitis perusahaan Ascentage Pharma Corp (AAPG)

- rega pasar lan target rega analis:
Bagan rega Ascentage Pharma|AAPG - Target median analis
- rincian kapitalisasi pasar:
Kapitalisasi pasar Ascentage Pharma Corp|AAPG - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- statistik nilai buku emiten:
Nilai Buku saben Saham Ascentage Pharma|AAPG - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku ascentage.com|AAPG - Total Aset Bisnis
- data tingkat utang lan likuiditas finansial:
Rasio Total Utang marang Ekuitas Ascentage Pharma Group|AAPG - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Ascentage Pharma Group|AAPG - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Ascentage Pharma Corp|AAPG - Tanggungan jangka dawa|Utang jangka cendhak perusahaan Ascentage Pharma|Indikator likuiditas cepet ascentage.com
- rincian asil keuangan lan kelipatan valuasi:
AAPG - Bathi pungkasan|Bathi sing dikarepake Ascentage Pharma Group|AAPG - Kapitalisasi marang bathi resik|Pangali Forward P/E Ascentage|AAPG - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Ascentage Pharma Corp|AAPG - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Ascentage Pharma|AAPG - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ascentage.com|AAPG - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Ascentage Pharma Group
- rincian pendapatan lan dodolan:
AAPG - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Ascentage Pharma|AAPG - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Ascentage Pharma Corp
Analisis fundamental perusahaan:Ascentage Pharma AAPG
Produk sing diprodhuksi Ascentage Pharma Corp

High uncertainty regarding the clinical trial outcomes of Ascentage Pharma Group (AAPG) anti-tumor drugs directly impacts market expectations for future sales. By analyzing the forward price-to-sales valuation trend, an investor can observe the ratio of current market capitalization to projected revenue, which determines the extent to which the cost of capital is inflated relative to the risks of commercial failure within the competitive oncology segment.

Pesaing utama

Rasio rega marang prakiraan pendapatan BeiGene ONC|Rasio kapitalisasi marang dodolan sing dikarepake Halozyme Therapeutics, Inc. (HALO)|RevMed - Multiplikator Forward P/S|CG Oncology Therapeutics (CGON) - Multiplikator forward rega marang pendapatan|URGN: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep bicara.com (BCAX)|Rasio rega marang prakiraan pendapatan Personalis|Kapitalisasi marang prakiraan pendapatan ERAS (Erasca Inc)|Multiplikator forward rega marang pendapatan DCTH (Delcath)|Rasio rega marang pendapatan sing dikarepake YMAB|Multiplikator Forward P/S AURA (Aura Biosciences, Inc.)|Multiplikator Forward P/S Candel Therapeutics Inc. CADL|Accuray - Multiplikator Forward P/S|Prakiraan rega marang pendapatan SELLAS Life Sciences (SLS)|ACTU: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Oncology Inc (CTOR)|Multiplikator forward rega marang pendapatan HURA|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|WHWK: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TCRX (TScan Therapeutics, Inc.)|Rega forward marang dodolan CSBR|XBiotech USA - Multiplikator Forward P/S|CVM - Multiplikator Forward P/S|OS Therapies (OSTX) - Rasio rega marang prakiraan pendapatan|radiopharmtheranostics.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Artiva Biotherapeutics Inc.|Multiplikator forward rega marang pendapatan Adlai Nortye Limited (ANL)|Multiplikator Forward P/S VERU|Multiplikator Forward P/S tempesttx.com (TPST)|Xilio Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan RENB|Mural Bio - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|CytoMed Therapeutics Limited - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Curis Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Apollomics Corp APLM|Multiplikator forward rega marang pendapatan THAR (Tharimmune Corp)|Multiplikator Forward P/S advanbiomed.com (ADVB)|Rasio rega marang prakiraan pendapatan Genprex, Inc. GNPX|CLDI (Calidi Biotherapeutics Inc.) - Rega mangsa ngarep marang pendapatan|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|XBIO - Multiplikator Forward P/S|SLRX: Multiplikator Forward P/S|Kitov Pharma (PPBT) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan American Oncology Network Inc|beigene.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CKPT|elevationoncology.com (ELEV) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|VIRX - Multiplikator Forward P/S|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NAYA|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S